# Compugen Ltd. share price today (Compugen Ltd., CGEN)

> Compugen Ltd.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CGEN · Healthcare · Biotechnology · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/cgen

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $2.01 (+13.6% in a year)
- P/E: 5.4× (lower than 78% of the last 10 months)
- Revenue (Jun 2026): $2.6 M (+107.0% on a year ago)
- Profit (Jun 2026), incl. one-off: −$7.0 M (one-off item, see below)
- Operating margin: −339.6% (+331.0 points on a year ago)
- ROE: 34%, FY25

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Compugen Ltd. share price today? Compugen Ltd.'s share price was $2.01 at the close on 3 November 2026. That is 12.2% below its average price over the last 200 trading days. In the last 52 weeks it traded between $2 and $3, and at that close it sat 31% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 6 weeks running. Over the last 1 year the share price moved +26% while the S&P 500 moved +21%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 25 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Compugen Ltd. pay? Compugen Ltd. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Compugen Ltd. on? Compugen Ltd. is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Compugen Ltd. profitable? Compugen Ltd. posted a net loss of $7.0 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. Full-year FY25 profit was $35.3 M. That loss is 269.3% of the quarter's revenue. The same quarter a year earlier lost $7.3 M. 9 of the last 12 reported quarters were loss-making. Read this profit with care: at −$7.0 M it is bigger than the quarter's whole revenue of $2.6 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −339.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Compugen Ltd. make, and is it growing? Compugen Ltd. reported $2.6 M of revenue in the Jun 2026 quarter, +107.0% on the same quarter a year earlier. Over 4 years it has grown 86.6% a year on average. The last full year, FY25, came in at $72.8 M. The last four reported quarters add to $74.0 M. FY25 revenue was $72.8 M, +161.1% on the year before. Recent pace: the last four quarters grew +1,122.7% on average, against 86.6% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +234.2%, against +21.4% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Compugen Ltd. keep? Compugen Ltd.'s operating margin was −339.6% in the Jun 2026 quarter, 331.0 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −584.6% and 43.1%. The latest quarter is within that range. Across 5 years it has been between −584.6% and 43.1%, and FY25's 43.1% is the highest of them. Why the margin moved: operating margin changed +331.0 percentage points on the year while gross margin changed +29.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Compugen Ltd.'s profit turning into cash? Compugen Ltd.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $31.6 M of operating cash against $35.3 M of profit. After $306 K of spending on assets, $31.3 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Compugen Ltd.'s cash go? Compugen Ltd. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $596 K on assets over the last 3 years. Averaged over those years that is 0.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $596 K over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Compugen Ltd.'s P/E ratio, and how does it compare with its own history? Compugen Ltd.'s P/E is 5.4×, near the low end of its own history: it has been lower only 22% of the time. Its usual P/E (the middle reading) is 6.1×, over 10 months of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Compugen Ltd. business getting better or worse? Compugen Ltd.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Compugen Ltd. earn on its capital? Compugen Ltd. earned a ROE of 34% in FY25. That is up from a low of −43% in FY22. Its return on capital used (ROIC) is 6.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 48.6% net margin and 0.46× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 48.6% net margin × 0.46× asset turnover × 1.52× leverage (assets divided by equity) ≈ 34.0% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 26.1% − 19.4% = +6.7 percentage points. The 19.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. The 26.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY23 at −208.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Compugen Ltd. have too much debt? Compugen Ltd. has total debt of $3.0 M against shareholder equity of $88.7 M as of Jun 2026, so its debt is 0.03× its equity, which is very little. Year by year, that ratio went from 0.03 in FY21 to 0.03 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Compugen Ltd. shareholding pattern? We have no ownership or short-position figures for Compugen Ltd., so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 13.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Compugen Ltd. from balance-sheet trouble? For Compugen Ltd., the Z-score is −0.40. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.40 is inside the danger zone, so the balance sheet is a real risk. ## How does Compugen Ltd. rank in its industry? There is no score against its industry: Compugen Ltd. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Compugen Ltd. compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Compugen Ltd. in size? Compugen Ltd. is the 196th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Artiva Biotherapeutics, Inc., Cartesian Therapeutics, Inc. and ProQR Therapeutics N.V. Just below it: Niagen Bioscience, Inc., Upstream Bio, Inc. and Whitehawk Therapeutics, Inc. ### Biotechnology companies close in size

1. [Artiva Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/artv) $205 million
2. [Cartesian Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rnac) $194 million
3. [ProQR Therapeutics N.V.](https://www.sectoralpha.in/us/stocks/prqr) $193 million
4. Compugen Ltd. $190 million
5. [Niagen Bioscience, Inc.](https://www.sectoralpha.in/us/stocks/nage) $187 million
6. [Upstream Bio, Inc.](https://www.sectoralpha.in/us/stocks/upb) $186 million
7. [Whitehawk Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/whwk) $177 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

## What else do people ask about Compugen Ltd.? ### What were Compugen Ltd. Ltd.'s latest quarterly results? Compugen Ltd. reported revenue of $2.6 M and a net loss of $7.0 M for the Jun 2026 quarter. Earnings per share were −$0.07. The operating margin was −339.6%, 331.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Compugen Ltd. Ltd.'s market cap? Compugen Ltd.'s market capitalisation is $190 M at a stock price of $2.01. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Compugen Ltd. Ltd. performing? Compugen Ltd.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 6 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Compugen Ltd. Ltd.'s stock price go up? This page does not forecast Compugen Ltd.'s stock price. What it shows instead: the stock price is $2.01. Its P/E of 5.4× is higher than 22% of its own last 1 years. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Compugen Ltd. Ltd. in its business cycle? Compugen Ltd.'s FY25 operating margin was 43.1%, against a 5-year range of −584.6% to 43.1%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was −339.6%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Compugen Ltd. Ltd. story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Compugen Ltd. Ltd. a stock worth studying right now? What the numbers show: Compugen Ltd.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.